Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen

Trial Profile

Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2016

At a glance

  • Drugs Eflapegrastim (Primary) ; Pegfilgrastim
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 12 Dec 2015 Results (n=147) presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 04 Nov 2015 Results will be presented at the San Antonio Breast Cancer Symposium 2015, according to a Spectrum Pharmaceuticals media release.
    • 09 Sep 2014 Status changed from active, no longer recruiting to completed, according to a Spectrum Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top